GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » EV-to-EBITDA

Imagion Biosystems (ASX:IBX) EV-to-EBITDA : -0.89 (As of Sep. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Imagion Biosystems's enterprise value is A$3.70 Mil. Imagion Biosystems's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was A$-4.14 Mil. Therefore, Imagion Biosystems's EV-to-EBITDA for today is -0.89.

The historical rank and industry rank for Imagion Biosystems's EV-to-EBITDA or its related term are showing as below:

ASX:IBX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.39   Med: -1.95   Max: 0.34
Current: -0.9

During the past 7 years, the highest EV-to-EBITDA of Imagion Biosystems was 0.34. The lowest was -27.39. And the median was -1.95.

ASX:IBX's EV-to-EBITDA is ranked worse than
100% of 114 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.17 vs ASX:IBX: -0.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-25), Imagion Biosystems's stock price is A$0.025. Imagion Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.184. Therefore, Imagion Biosystems's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Imagion Biosystems EV-to-EBITDA Historical Data

The historical data trend for Imagion Biosystems's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems EV-to-EBITDA Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -3.13 -26.46 -12.80 -3.11 -1.69

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.11 - -1.69 -

Competitive Comparison of Imagion Biosystems's EV-to-EBITDA

For the Diagnostics & Research subindustry, Imagion Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagion Biosystems's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's EV-to-EBITDA falls into.



Imagion Biosystems EV-to-EBITDA Calculation

Imagion Biosystems's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.699/-4.142
=-0.89

Imagion Biosystems's current Enterprise Value is A$3.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was A$-4.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imagion Biosystems  (ASX:IBX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Imagion Biosystems's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.025/-0.184
=At Loss

Imagion Biosystems's share price for today is A$0.025.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imagion Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.184.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Imagion Biosystems EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Imagion Biosystems Business Description

Traded in Other Exchanges
Address
5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines